Evidence map›Paper›PMID 41384245›Full record

ArticleFrontiers in physiology2025

Tracking hemopexin intracellularly and defining hemopexin protein "interactomes" in human immune and liver cell models.

Bryan Rose, David Moore, Jeff Eskew, Roberto Vanacore, Steve D Hartson, Dennis Province, D Andrew Skaff, Ann Smith

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bryan RoseUMKC School of Science and Engineering, Biological and Biomedical Systems, Kansas City, MO, United States.
David MooreUMKC School of Dentistry, Kansas City, MO, United States.
Jeff EskewPoseida Therapeutics Inc., San Diego, CA, United States.
Roberto VanacoreDivision of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, United States.
Steve D HartsonOklahoma State University, Stillwater, OK, United States.
Dennis ProvinceIDeA National Resource for Quantitative Proteomics, U. of Arkansas for Medical Sciences, Little Rock, AR, United States.
D Andrew SkaffEir Pharmaceuticals, LLC, Olathe, KS, United States.
Ann SmithUMKC School of Science and Engineering, Biological and Biomedical Systems, Kansas City, MO, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Maintaining hemopexin (HPX) plasma levels protects against heme-activated inflammation as well as the toxicity of heme and its iron during hemolysis. Plasma heme regulates HPX turnover in hepatocytes, thus controlling plasma HPX concentration. Heme from heme-HPX is delivered to the liver, and apo-HPX recycles without degradation. The scavenger receptor, low-density lipoprotein-related protein 1 (LRP1), binds heme-HPX and targets it for lysosomal degradation. Nevertheless, heme-HPX endocytosis also occurs in mouse embryonic fibroblast LRP1

Indexed as

hemolysishemopexinhemostasishuman hepatocytesinflammation controllow density lipoprotein receptor 1receptortransferrin receptor 1

Identifiers

PMID41384245
PMCPMC12690290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.